CN115362175A - 抗acvr1抗体及其用途 - Google Patents

抗acvr1抗体及其用途 Download PDF

Info

Publication number
CN115362175A
CN115362175A CN202180027355.8A CN202180027355A CN115362175A CN 115362175 A CN115362175 A CN 115362175A CN 202180027355 A CN202180027355 A CN 202180027355A CN 115362175 A CN115362175 A CN 115362175A
Authority
CN
China
Prior art keywords
antibody
ser
acvr1
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027355.8A
Other languages
English (en)
Chinese (zh)
Inventor
V·J·艾旦
S·J·哈特塞尔
A·N·伊科诺米迪斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN115362175A publication Critical patent/CN115362175A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180027355.8A 2020-02-11 2021-02-10 抗acvr1抗体及其用途 Pending CN115362175A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062975047P 2020-02-11 2020-02-11
US62/975,047 2020-02-11
US202063030131P 2020-05-26 2020-05-26
US63/030,131 2020-05-26
PCT/US2021/017427 WO2021163170A1 (en) 2020-02-11 2021-02-10 Anti-acvr1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN115362175A true CN115362175A (zh) 2022-11-18

Family

ID=74860418

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027355.8A Pending CN115362175A (zh) 2020-02-11 2021-02-10 抗acvr1抗体及其用途

Country Status (11)

Country Link
US (2) US11945872B2 (cg-RX-API-DMAC7.html)
EP (1) EP4103617A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023519100A (cg-RX-API-DMAC7.html)
KR (1) KR20220140802A (cg-RX-API-DMAC7.html)
CN (1) CN115362175A (cg-RX-API-DMAC7.html)
AU (1) AU2021218675A1 (cg-RX-API-DMAC7.html)
CA (1) CA3167441A1 (cg-RX-API-DMAC7.html)
IL (1) IL295419A (cg-RX-API-DMAC7.html)
MX (1) MX2022009769A (cg-RX-API-DMAC7.html)
WO (1) WO2021163170A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202208222B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019364415A1 (en) 2018-10-23 2021-05-20 Keros Therapeutics, Inc. ALK2 antibodies and methods of use thereof
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
CN119529092A (zh) * 2021-09-03 2025-02-28 来凯医药科技(上海)有限公司 抗acvr2a抗体及其用途
WO2024092133A1 (en) 2022-10-27 2024-05-02 Regeneron Pharmaceuticals, Inc. Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101160055A (zh) * 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
CN107106648A (zh) * 2014-09-12 2017-08-29 瑞泽恩制药公司 进行性骨化性纤维发育不良的治疗
CN107207589A (zh) * 2014-09-23 2017-09-26 瑞泽恩制药公司 抗il‑25抗体及其使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US8859752B2 (en) 2006-04-18 2014-10-14 The Trustees Of The University Of Pennsylvania SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
US8895711B2 (en) * 2006-04-18 2014-11-25 The Trustees Of The University Of Pennsylvania Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
RS53258B (sr) 2007-02-21 2014-08-29 University Of Massachusetts Humana antitela protiv virusa hepatitisa c (hcv) i njihove upotrebe
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素a之抗體及其用途
WO2016121908A1 (ja) * 2015-01-30 2016-08-04 学校法人埼玉医科大学 抗alk2抗体
CN111836643A (zh) 2018-03-05 2020-10-27 学校法人埼玉医科大学 用于治疗或预防异位骨化的药物组合物
KR20210038906A (ko) * 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
AU2019364415A1 (en) 2018-10-23 2021-05-20 Keros Therapeutics, Inc. ALK2 antibodies and methods of use thereof
US12428484B2 (en) 2018-12-06 2025-09-30 Alexion Pharmaceuticals, Inc. Anti-ALK2 antibodies and uses thereof
EP4008350A4 (en) 2019-07-26 2023-06-14 Saitama Medical University ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101160055A (zh) * 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
CN107106648A (zh) * 2014-09-12 2017-08-29 瑞泽恩制药公司 进行性骨化性纤维发育不良的治疗
CN107207589A (zh) * 2014-09-23 2017-09-26 瑞泽恩制药公司 抗il‑25抗体及其使用方法

Also Published As

Publication number Publication date
WO2021163170A1 (en) 2021-08-19
CA3167441A1 (en) 2021-08-19
ZA202208222B (en) 2023-10-25
IL295419A (en) 2022-10-01
EP4103617A1 (en) 2022-12-21
US11945872B2 (en) 2024-04-02
AU2021218675A1 (en) 2022-08-18
KR20220140802A (ko) 2022-10-18
US20210253716A1 (en) 2021-08-19
US20240190974A1 (en) 2024-06-13
JP2023519100A (ja) 2023-05-10
MX2022009769A (es) 2022-11-09

Similar Documents

Publication Publication Date Title
KR102831970B1 (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
CN110869389B (zh) 抗ror1抗体及其制备和使用方法
AU2024200534A1 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
DK2519543T3 (en) HETERODIMER BINDING PROTEINS AND USE THEREOF
KR102551269B1 (ko) 저-점도 항원 결합 단백질 및 이의 제조 방법
KR102161460B1 (ko) St2 항원 결합 단백질
KR101262032B1 (ko) MAdCAM에 대한 항체
CN111954680B (zh) IL2Rβ/共同γ链抗体
KR101963923B1 (ko) 이중특이적 t 세포 활성화 항원 결합 분자
TW202539736A (zh) 對胃抑肽受體(gipr)具特異性之抗原結合蛋白之用途
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
KR20220140802A (ko) 항-acvr1 항체 및 이의 용도
KR20230017815A (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
KR20220042137A (ko) 항-뉴욕 식도 편평 세포 암종 1 (ny-eso-1) 항원-결합 단백질 및 이의 사용 방법
KR20230027300A (ko) Il-10 뮤테인 및 이의 융합 단백질
KR102787394B1 (ko) MAdCAM에 대한 항체
CN114502151B (zh) 抗cd19抗体及其使用和制备方法
CN117460747A (zh) 靶向CD79b、CD20和CD3的三特异性抗体
US20240150474A1 (en) Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification
RU2800649C2 (ru) Моноклональные антитела против рецептор-связывающего домена spike-белка вируса sars-cov-2 и их антигенсвязывающие фрагменты, кодирующие их нуклеиновые кислоты, а также способы применения
KR20210123350A (ko) 항-il2 수용체 감마 항원-결합 단백질
EA044746B1 (ru) АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ ПРОТИВ ГЛИКОПРОТЕИНА ШИПОВ SARS-CoV-2
HK40020170A (en) Bispecific t cell activating antigen binding molecules
HK1242713A1 (en) T cell activating bispecific antigen binding molecules agiant folr1 and cd3

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination